These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28619423)

  • 21. The outlook for alemtuzumab in multiple sclerosis.
    Williams T; Coles A; Azzopardi L
    BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glomerulonephritis With Positive Anti-Glomerular Basement Membrane Antibodies Following Alemtuzumab Treatment.
    White E; Watson A; Holian J; McGuigan C; O'Riordan S
    Ir Med J; 2020 Mar; 113(3):41. PubMed ID: 32815683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
    J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity.
    Bianco A; Nicoletti T; Traini E; Del Giacomo P; Del Gatto V; Lucchini M; Rota CA; Mirabella M
    J Endocrinol Invest; 2020 Aug; 43(8):1159-1161. PubMed ID: 32130689
    [No Abstract]   [Full Text] [Related]  

  • 26. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Meunier B; Rico A; Seguier J; Boutiere C; Ebbo M; Harle JR; Schleinitz N; Pelletier J
    Mult Scler; 2018 May; 24(6):811-813. PubMed ID: 29359614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS.
    Pfeuffer S; Beuker C; Ruck T; Lenze F; Wiendl H; Melzer N; Meuth SG
    Neurology; 2016 Nov; 87(22):2380-2381. PubMed ID: 27794114
    [No Abstract]   [Full Text] [Related]  

  • 28. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
    Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
    Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis.
    Buonomo AR; Zappulo E; Viceconte G; Scotto R; Borgia G; Gentile I
    Expert Opin Drug Saf; 2018 Jul; 17(7):709-717. PubMed ID: 29848085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
    Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
    Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
    Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
    Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient.
    Kogel AK; Gold R; Schneider R
    J Neurol; 2021 Nov; 268(11):4374-4375. PubMed ID: 34175973
    [No Abstract]   [Full Text] [Related]  

  • 33. Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
    Ahrabian D; Neill L; Bell R; Leary SM
    Mult Scler; 2020 May; 26(6):735-737. PubMed ID: 32298216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.
    Yiannopoulou KG; Papadimitriou D; Anastasiou AI; Siakantaris M
    Mult Scler Relat Disord; 2018 Jul; 23():15-16. PubMed ID: 29730587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
    Romero A; Midaglia L; Salcedo MT; Viladomiu L; Guillén E; Bajaña I; Escolà-Vergé L; Tintoré M; Montalban X; Len O
    Mult Scler Relat Disord; 2020 May; 40():101973. PubMed ID: 32028116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration of Alemtuzumab: A Case Report.
    Liou AA; Skiver BM; Yates E; Persad P; Meyer D; Farland AM; Rocco MV
    Am J Kidney Dis; 2019 May; 73(5):615-619. PubMed ID: 30528935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis.
    Penkert H; Delbridge C; Wantia N; Wiestler B; Korn T
    JAMA Neurol; 2016 Jun; 73(6):757-9. PubMed ID: 27043129
    [No Abstract]   [Full Text] [Related]  

  • 38. Disseminated herpes zoster infection 16 months after last intake of alemtuzumab: potential long-term adverse effects.
    Albrecht LJ; Moelleken M; Dissemond J
    Clin Exp Dermatol; 2021 Apr; 46(3):550-552. PubMed ID: 32810347
    [No Abstract]   [Full Text] [Related]  

  • 39. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
    Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
    Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy, and stroke: A case report.
    Alnahdi MA; Aljarba SI; Al Malik YM
    Mult Scler Relat Disord; 2020 Jun; 41():102141. PubMed ID: 32446212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.